WO1988009171A1 - Phosphoethanolamine permettant le traitement de la maladie d'alzheimer - Google Patents
Phosphoethanolamine permettant le traitement de la maladie d'alzheimer Download PDFInfo
- Publication number
- WO1988009171A1 WO1988009171A1 PCT/US1988/001693 US8801693W WO8809171A1 WO 1988009171 A1 WO1988009171 A1 WO 1988009171A1 US 8801693 W US8801693 W US 8801693W WO 8809171 A1 WO8809171 A1 WO 8809171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hydrogen
- alzheimer
- pharmaceutically acceptable
- dementia
- Prior art date
Links
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000001965 increasing effect Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 28
- 206010012289 Dementia Diseases 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 208000012902 Nervous system disease Diseases 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- ZWIADYZPOWUWEW-UHFFFAOYSA-N Cytidine 5'-diphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-UHFFFAOYSA-N 0.000 claims description 4
- ZWIADYZPOWUWEW-ZAKLUEHWSA-N cytidine-5'-diphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO[P@](O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-ZAKLUEHWSA-N 0.000 claims description 4
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- WVIMUEUQJFPNDK-PEBGCTIMSA-N CDP-ethanolamine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCCN)O[C@H]1N1C(=O)N=C(N)C=C1 WVIMUEUQJFPNDK-PEBGCTIMSA-N 0.000 claims description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 2
- 108020002494 acetyltransferase Proteins 0.000 claims description 2
- 102000005421 acetyltransferase Human genes 0.000 claims description 2
- 230000031018 biological processes and functions Effects 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 claims 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 claims 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 abstract description 31
- 210000004556 brain Anatomy 0.000 abstract description 20
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 19
- 229960004373 acetylcholine Drugs 0.000 abstract description 18
- 210000002813 septal nuclei Anatomy 0.000 abstract description 10
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 20
- 239000000872 buffer Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical class S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 13
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 11
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000001320 hippocampus Anatomy 0.000 description 10
- 238000000746 purification Methods 0.000 description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000027089 Parkinsonian disease Diseases 0.000 description 5
- 206010034010 Parkinsonism Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- 210000002932 cholinergic neuron Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229940117953 phenylisothiocyanate Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 210000001905 globus pallidus Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008760 nerve sprouting Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YJHSJERLYWNLQL-UHFFFAOYSA-N 2-hydroxyethyl(dimethyl)azanium;chloride Chemical compound Cl.CN(C)CCO YJHSJERLYWNLQL-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 102000002745 Choline Kinase Human genes 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 108010018888 Choline kinase Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000434 field desorption mass spectrometry Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003152 propanolamines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010073191 somatostatin-like peptides Proteins 0.000 description 1
- 230000003294 somatostatinlike Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000004057 substantia innominata Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- the field of the invention is providing pharmaceutical compositions for the treatment of neurological disorders associated with dementia, such as Alzheimer's disease.
- Alzheimer's disease is a disorder of the later decades of life characterized by dementia. In clinical terms, it consists of a diffuse deterioration of mental function, primarily in thought and memory, and secondarily in feeling and conduct. Alzheimer's disease has been used to designate dementia appearing before the age of 65 years. When the syndrome presents after that age, the term senile dementia of the Alzheimer's type is used. In fact, it appears reasonable to consider both types as representing a single syndrome. The true incidence of the disorder is unknown, although recent data suggest that the incidence of all dementia in the U.S. population may be over 100 cases per 100,000, with its prevalence being over 550 per 100,000 [1].
- Alzheimer's disease probably affects at least 30 to 50% of patients with dementia, and in the United States there may be over one million individuals with severe dementia and several million more with mild to moderate dementia. It has been estimated that 1 out of every 6 persons over the age of 65 in the United States suffers from moderate dementia, and a majority of patients in the nursing home populations are affected with the disorder. The average age of onset is between 70 and 79 years, but without better information on the population at risk, a more accurate statement is not presently possible [1]. As in ALS and parkinsonism, the incidence of the syndrome clearly increases with advancing age. A family history of Alzheimer's disease is present in 5 to 10% of the patients.
- Alzheimer's disease is one of exclusion. Secondary causes of loss of memory and impaired cognitive function may result from multiple infarcts, leading to so-called multinfarct dementia, or from intracranial mass lesions such as subdural hematomas, brain tumors, or granulomas. Central nervous system infections of viral and bacterial origin, or even slow viral disorders such as Jakob- Creutzfeldt disease, are part of the differential diagnosis. Furthermore, metabolic disorders involving vitamin B ⁇ metabolism, thiamine or folate deficiency, thyroid dysfunction, hepatic and renal failure, as well as drug toxicity, may present as dementia.
- the pathological picture of Alzheimer's disease has been well characterized over the years. It consists of senile plaques, which result from degeneration of nerve endings, and neurofibrillary tangles, which represent an alteration in the cytoskeletal apparatus [4].
- senile plaques which result from degeneration of nerve endings
- neurofibrillary tangles which represent an alteration in the cytoskeletal apparatus [4].
- intracellular cytoplasmic eosinophilic inclusions termed Hirano bodies, are present, primarily in the hippocampus. Granulovacuolar degeneration is also noted.
- Senile plaques and neurofibrillary tangles in the brain are part of the "normal" aging process. However, at any age, patients with clinical Alzheimer's disease appear to have much higher concentration of these abnormalities than do normal individuals [5].
- a prominent finding in Alzheimer's disease is a deficiency of the enzyme that synthesizes the neurotransmitter acetylcholine, namely, choline acetyltransferase (CAT) [6].
- This deficiency is most marked in the cortex and hippocampus.
- acetylcholine receptors in the brain are either unaffected or relatively less affected.
- the defect in CAT reflects an alteration in the presynaptic cholinergic neuron.
- the diminution in CAT correlates with the pres- ence of senile plaques: the greater the number of plaques, the lower the activity of CAT.
- Enzymes synthesizing several other neurotransmitters including dopamine, norepinephrine, serotonin, and gamma- aminobutyric acid, as well as levels of vasoactive intestinal peptide, are all relatively unaffected compared to the loss of CAT activity. Somatostatin-like activity has recently been reported to be decreased in the cerebral cortex [7].
- the CAT activity found in the hippocampus appears to derive largely from nerve terminals for which the cell of origin is in the septal nucleus.
- almost 70% of CAT activity in the cortex appears to reside in terminals with cell bodies located in the nucleus basalis of Meynert [8].
- these cholinergic neurons lie intermingled with and beneath the medial globus pallidus, whereas in primates comparable cells are found exclusively outside the pallidum.
- the nucleus basalis of Meynert is situated in the fibrous zone beneath the globus pallidus and is a major component of the substantial innominata [9].
- the cholinergic input to hippocampus and cortex may derive from a group of cells extending from the septal nuclei to constituents of the substantia innominata and may well be impaired in Alzheimer's disease [9].
- the following references are relevant to the invention:
- Bottenstein JE, Sato GH Growth of a rat neuroblastoma cell line in serum-free supplemented media. Proc Natl Acad Sci USA 76:514-517, 1979
- Finch CE Catecholamine metabolism in the brains of aging male mice. Brain Res 52:261-276, 1973
- Fonnum F Radiochemical micro assays for the determination of choline acetyltransferase and acetycholinesterase activities. Biochem J 115:465-472, 1969
- Hemmendinger LM Garber BB, Hoffman PC, Heller A: Target neuron-specific process formation by embryonic mesencephalic dopamine neurons in vitro. Proc Natl Acad Sci USA 78:1264- 1268, 1981
- U.S. Patent 4,294,818 discloses a diagnostic method for multiple sclerosis comprised of antibody preparations reactive with antigenic substances associated with lymphocytes.
- U.S. Patent 3,864,481 discloses a synthetic amino acid for suppression and diagnosis of multiple sclerosis.
- the present invention is based upon the discovery that phosphoethanolamine, a natural product isolated from the brains of animals, and related compounds are cholinergic fac- tors in that treatment of explant cultures of medial septal nuclei with phosphoethanolamine or related compounds results in an increased capacity of these cultures to synthesize the neurotransmitter acetylcholine.
- Treatment of Alzheimer's disease with cholinergic factors is based upon the ability of these compounds to improve the function of acetylcholine producing neurons which are impaired in Alzheimer's disease.
- the present invention discloses a method of treating a patient having a neurological disorder associated with dementia of the Alzheimer's type comprising administering to said patient an amount of a composition effective in amelioration of the dementia comprising a pharmaceutically acceptable excipient and an active sterioisomeric form of a compound having the structure
- R 1 is hydrogen or a lower alkyl
- the R 2 and R 3 groups may each be hydrogen, or different groups selected from the group consisting of hydrogen, the lower alkyls, and -COOM groups wherein M is hydrogen or a pharmaceutically acceptable cation
- R 4 is selected from the group consisting of -OH, -PO 3 H 2 , -OPO 3 H 2 , cytidine 5'-diphosphate, and their pharmaceutically acceptable salts.
- an object of the present invention to provide an effective treatment for patients suffering from central nervous system disorders, especially those connected with cerebral senescence, such as Alzheimer's disease. Patients are treated by administering an effective amount of an active sterioisomeric form of a compound of the present invention which is in admixture with a pharmaceutically acceptable excipient.
- a further object of the present invention is to provide numerous compounds which are effective in increasing the synthesis of acetyltransferase, and therefore are available for use in the treatment of neurological disorders.
- Figure 1 depicts a flow chart for the purification of the central cholinergic factor isolated from brain extracts.
- Figure 2 is an illustration of a mass spectrometric analysis of the phenylisothiocyanate derivatives of a central cholinergic factor isolated from cortical and hippocampal tissues.
- ALS represents pathological change in Betz cells, cranial motor neurons, and anterior horn cells; parkinsonism, in substantial nigra neurons; and Alzheimer's disease, in the cholinergic input from nucleus basalis and septal neurons to cortex and hippocampus, respectively.
- compositions of the present invention are a modification of the notion of intrinsic aging of selected neurons; that is, the presence of specific extrinsic factors influence the maintenance and survival of neurons.
- system degeneration Is due to diminished availability of a specific neurotrophic factor normally released by the post-synaptic cell, taken up by the presynaptic terminal, and exerting its effect by retrograde transport up the presynaptic axon to the soma and nucleus.
- cholinergic factors can be demonstrated in vitro which increase the activity of the neurotransmitter synthesis enzymes in the innervating cell.
- the same factors responsible for increasing neurotransmitter synthesis in vitro may also be responsible for increasing neurotransmitter synthesis in vivo.
- a well-defined cholinergic system in the rat brain and one that is analogous to the neuronal networks affected in Alzheimer's disease is the projection from the medial septal nucleus to the hippocampus.
- the septo-hippocampal system has been extensively studied with respect to its anatomic relations, developmental neurogenesis, neurotransmitter distribution and capacity for regeneration.
- Explant cultures of the medial septal nucleus are organotypic such that the associations with glia and other neurons are maintained in the microenvironment of the cholinergic neurons .
- the in vitro development of cholinergic parameters in such cultures may therefore closely resemble those which normally occur in vivo.
- Biological compounds added to these cultures which result in the enhancement of these properties would be expected to exist outside the immediate embryonic environment of these neurons. These cultures are therefore suitable for observing the pharmacologic effect of putative cholinergic factors on these cultures. Similar or related factors may also be indirectly responsible for maintenance of neurons throughout the life cycle in vivo, and may decrease as a normal function of aging.
- a primary manifestation of ALS, Parkinson disease, or Alzheimer's disease is failure of the target tissue to supply the necessary neurotrophic factor. Marked pathological change in the tissue need not be present. Impaired synthesis or release (or both) of the relevant hormone would represent the sine qua non of disease. For example, in Alzheimer's disease, the failure would be in hippocampus and cortical cell to supply the relevant cholinergic neurotrophic factor. Thus, in this system, the lack of an appropriate factor released from post-synaptic cells impairs the viability of the presynaptic cells and leads to the gradual deterioration of septal and basal nuclei.
- the present invention discloses a pharmaceutical composition for the treatment of a patient having a neurological disorder associateded with dementia of the Alzheimer's type wherein said pharmaceutical composition comprises a pharmaceutically acceptable excipient and an effective amount of an active sterioisomeric form of a compound having the structure
- R 1 is hydrogen or a lower alkyl
- the R 2 and R 3 groups may be the same when hydrogen, or different and are selected from the group consisting of hydrogen, the lower alkyls, and -COOM groups wherein M is hydrogen or a pharmaceutically acceptable cation
- R 4 is selected from the group consisting of -OH, -PO 3 ,H 2 , -OPO 3 H 2 , cytidine 5'-diphosphate, and their pharmaceutically acceptable salts.
- Also disclosed is a method of treating a patient having a neurological disorder associated with dementia which method comprises administering to said patient an effective dementia-treating amount of the pharmaceutical composition of the invention.
- “Lower alkyl” means a branched or unbranched saturated hydrocarbon group of one to eight carbon atoms such as , methyl, ethyl, i-propyl and n-butyl and the like.
- “Pharmaceutically acceptable cations or anions”, or “pharmaceutically acceptable salts” refers to any cation or anion which is pharmaceutically consistent with the mode of administration and does not produce any untoward pharmaceutical effects. Thus, cations may include ions.
- alkali metalsand alkaline earth and transition metals such as calcium, barium, magnesium, sodium, zinc and potassium
- anions may include ions of the mineral acids such as halides, nitrates, sulfates, or phosphates as well as anions of organic acids such as acetate and gluconate.
- “Pharmacological precursor” means any biological precursor of the present compounds set forth in the structural formula given in the Summary of the Invention which, upon breakdown of the precursor by normal biological processes, releases serine, phosphoserine, ethanolamine or phosphoethanolamine such that an increase in the levels of these latter compounds in the central nervous system occurs.
- “Active sterioisomeric form” of the present invention is intended to include racemic mixtures composed of varying concentrations of both active and inactive racemates but in such ratios that the overall racemic mixture is effec- tive in stimulating acetylcholine sythesis in cultures of septal neurons, an index of cholinergic maturation.
- compositions of the invention which are set forth in the structural formula given in the Summary of the Invention are well known and are commercially available.
- phosphoethanolamine, phosphoserine, CDP- ethanolamine and ethanolamine are available from Sigma (St. Louis, MO).
- Monomethylethanolamine and the active propanol compounds are available from Aldrich Chemical Co., Inc. (Milwaukee, WI).
- R 4 derivatives of ethanolamine and serine of the present invention are commercially available and can be used to construct the R 1 substituted compounds disclosed in this invention by reaction with activated alkyl and activated amino acid derivatives.
- R 1 substituted compounds used in this invention can be prepared as follows.
- R 1 is an alkyl group
- the compound is obtained through one of numerous procedures for N-alkylation that are well known in the art.
- alkyl halides react readily with amines to yield N-alkylated derivatives. Therefore, the reaction of R 1 -X wherein X is a halogen such as Br or Cl with the appropriate R. substituted ethanolamine or serine results in the R 1 -N derivative.
- Another method is reductive alkylation in which the appropriate activated carboxylic acid derivative of the alkyl reacts with an amino group resulting in the amide condensation product which may then be reduced to give the R 1 -N derivative.
- the R 1 derivatives may be produced first followed by esterification to yield the appropriate activated R 4 group.
- Methods for activating phosphate groups in order to obtain phosphate esters by condensation with alcohols are well known in the art.
- the reactive group on the R 4 substituent may be protected during the alkylation reaction, for example, by derivatization with a tertbutyloxycarbonyl group.
- phosphoethanolamine has been identified as a brain derived cholinergic factor present in corti- cal and hippocampal tissues.
- the discovery that phosphoethanolamine is effective in the treatment of Alzheimer's disease was made through efforts to isolate cholinergic factors from the target regions of cholinergic innervation in the brain, such as cortical and hippocampal brain tissues.
- Phosphoethanolamine was isolated using the purification scheme outlined in Figure 1 and assaying for stimulation of acetylcholine synthesis in the appropriate assay system described below.
- brain tissue containing the cortex, hippocampus and striatum from young rats and/or calves was homogenized in a buffer solution such as phosphate-buffered saline (PBS) and centrifuged to yield a crude extract.
- PBS phosphate-buffered saline
- the supernatant was acidified using acetic acid (1 to 2 M) and then recentrifuged.
- an appropriate filter for example, an Amicon YM-5 filter.
- the extracted factor may be directly purified by gel filtration chromatography using an appropriate matrix, such as a Biogel P-2 polyacrylamide column, to resolve proteins having molecular weights less than 1,500 daltons.
- fractionation procedures which can be used singly or in combination to increase purity of a composition are well known in the art. These include size fractionation using molecular sieve (or gel filtration) chromatography, ion exchange chromatography under suitable conditions; affinity chromatography using, for example, antibodies directed to the biologically active form of the neurotrophic factor; absorp tion chromatography using nonspecific supports, such as hydroxyapatite, silica, alumia, and so forth; and also gel- supported electrophoresis.
- the cholinergic factor in fractions corresponding to an apparent molecular weigh to the ⁇ 1,000 daltons, is eluted from a P-2 gel filtration column.
- the cholinergic factor is then bound to an anion exchange column (AG-1-X2) at ⁇ pH 8.5 in low salt and then eluted with a low pH (pH 5-5), high ionic strength buffer.
- AG-1-X2 anion exchange column
- Final purification can be achieved by cycling and recycling over different reverse phase matrices which effectively remove most protein since the active factor does not bind to these matrices in 0.1% trifluoroacetic acid (TFA).
- the ⁇ 1,000 dalton cholinergic factor was assayed on explant cultures of septal neurons obtained from mammalian species. It is preferred to use explants of the medial septal nuclei obtained from the forebrains of E16 rat embryos.
- the preferred method of assay is to incubate explants of rat septal nuclei with or without the cholinergic compounds for 6 days and then to measure the effect of the compound on the ability of the cells to synthesize acetylcholine.
- Assays employing survival, cell growth or the enhancement of other cholinergic properties in this and other types of cultures can also be used to assay for these neurotrophic compounds.
- Phosphoethanolamine has been purified from the target regions of cholinergic innervation in the rat and has been shown to enhance the ability of medial septal explants to synthesize acetylcholine, an Index of cholinergic maturation. Since phosphoethanolamine is effective in enhancing the in vitro cholinergic properties of neurons, the exogenous administration of this and related compounds may be an effective therapy in cases of Alzheimer's disease and general aging of the nervous system if cholinergic function is enhanced in vivo.
- compositions of this invention are useful for parenteral administration, for example, intravenous, sub- cutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intrasternal, topical, intranasal aerosol, scarification, and also for oral administration.
- the compositions can be formulated for parenteral administration to humans or other mammals in therapeutically effective amounts (e.g., amounts which eliminate or reduce the patient's pathological condition) to provide therapy for Alzheimer's disease.
- compositions can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers.
- pharmaceutically acceptable nontoxic excipients and carriers may be prepared for use for parenteral (subcutaneous, intramuscular, intraspinal, or Intravenous) administration particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops or aerosols.
- compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 1970.
- Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as poly- ethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
- Formulations for inhalation administration contain as excipients, for example, lactose or may be aqueous, such as glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops .
- the materials of this invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients .
- the concentration of the compounds described herein in a therapeutic composition will vary depending on a number of factors, including the dosage of the drug to be administered, the chemical characteristics, e.g., hydrophobicity of the compounds employed, and the mode of administration.
- the neurotrophic compounds are provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v factor for parenteral administration. Typical dose ranges are from about 10 ug/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 1 mg/kg to 100 mg/kg of body weight per day.
- the present invention will be further illustrated by the following examples. These examples are not to be construed as limiting the scope of the invention, which is to be determined solely by the appended claims.
- the filtrate was lyophilized, redissolved in 0.2 M acetic acid (0.05 times the original volume), filtered and applied to a 2.5 x 100 cm Bio-Rad P-2 column for chromatography in the same buffer.
- the elution profile was monitored at 0.D.280, and a peak with an apparent molecular weight of 1000 daltons was collected, lyophilized and redissolved in a buffer containing 130 mM N-ethylmorpholine, 250 mM pyridine, and 17 mM acetic acid, pH 8.3 (Buffer A).
- the lyophilized extract was resuspended in 50 ml/ 0.2 M acetic acid, and a slight insoluble residue removed by filtration through a 0.45 u filter prior to application on a P-2 polyacrylamide molecular sieving column.
- Molecular sieving was accomplished on a 5 x 140 cm column (Bio-Rad) eluted with 0.2 M acetic acid at a linear flow rate of 5 cm/hr. Fractions were collected only in the molecular weight range, including the void volume, through 700 mw. The fractions were assayed in the tissue culture system outlined below. The peak of activity migrating near 1000 mw was pooled and lyophilized to dryness.
- Example 3 Assay Method for Stimulation of Acetylcholine Synthesis In Explants of the Medial Septal Nucleus Whole septal nuclei were dissected from the forebrains of 16 day old rat embryos (ED 0 being the day of sperm positivity). The dorsal, caudal and lateral tissues were removed and the remaining medial fragments were sectioned into 0.3 mm pieces by pressing a nickel grid (Ladd Research, #10080) over them.
- a modified N 2 defined medium consisting of insulin (5 ug/ml), transferrin (100 ug/ml), putrescine (100 uM), progesterone (20 nM), selenium (30 nM), glutamine (4 mM),vitamin B-12 (350 nM) and gentamicin (50 ug/ml) in high glucose (0.6%) DMEM.
- Cultures were maintained in a humidified atmosphere of 5% CO 2 at 37°C Cultures were fed two days after plating by removing 0.5 ml of the plating medium and adding 1.0 ml of fresh medium containing a 2% rabbit serum supplement and the substances being tested. Partially purified fractions were lyophilized and redissolved at concentrations ranging from 10 ng to 1 ug protein per ml. Phosphoethanolamine purified from rat brain and authentic compounds purchased from Sigma Chemical Co. (St. Louis, MO) or Aldrich Chemical Co.
- Total [3H] dpm was calculated relative to the recovery of [14C] dpm and the net [3H] dpm was determined by subtracting the [3H] dpm recovered from culture dishes without explants.
- the activity of a compound was measured by calculating the increase in [3H] acetylcholine formed per explant as compared to that of nontreated control cultures.
- a unit of activity was defined as the amount of material needed to give a stimulation equal to 50% of the maximum response, which was typically a 2-fold Increase over controls.
- Phosphoethanolamine gave a maximal saturating response at 3 x 10 -5 molar, thereby exhibiting an ⁇ 2.2 fold increase over controls.
- Example 4 Structure Determination The highly purified rC-CF (rat) was analyzed for amino acid content. The results suggested the presence of an unexpectedly large amount of a compound with molecular weight of 141. The only additional component present had a molecular weight of 531 and was a minor component. Amino acid analysis of a lesser amount of material indicated the presence of a very large amount of a primary amine which was not a known amino acid. Based on the absorption of the phenylisothiocyanate (PITC) derivative, there were ⁇ 8 micromoles of this amine in the entire preparation from 250 brains.
- PITC phenylisothiocyanate
- FIG. 2A depicts the mass spectrometric profile of the isolated PITC derivatives of acid hydrolyzed rC-CF. Acid hydrolysis of phosphoethanolamine should yield ethanolamine, which would react with PITC to generate a derivative of mass 195 daltons. In fact, a (protonated) molecular ion of 196 is actually observed in field desorption mass spectroscopy.
- Figure 2B depicts the mass spectrometric profile of the puri- fied PITC derivative of rC-CF without acid hydrolysis.
- Example 6 Activities of Compound Analogs Compounds related to phosphoethanolamine were assayed in substantial accordance with the teaching of Example 3. Cultures of medial septal explants, which had been treated for six days with two additions of the compound of interest, were examined for their ability to convert choline to acetylcholine. A dose-response curved (1 uM to 1 mM) was generated for each compound to determine the effect on acetylcholine synthesis. The results of these experiments are provided in Table 2. As used therein, 1 unit of activity is equal to the molar concentration of the compound required to enhance acetylcholine synthesis 2-fold relative to untreated controls. EC 50 is the molar concentration at which 50% of the maximum stimulation is induced. These data taken together support the specificityect of ethanolamine and ethanolamine-like compounds in the present invention, on cholinergic neurons.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention est basée sur la découverte du fait que la phosphoéthanolamine, produit naturel isolé à partir du cerveau d'animaux, ainsi que des composés apparentés, sont des facteurs cholinergiques; en effet, le traitement de cultures d'explants de noyaux septaux médians avec la phosphoéthanolamine ou avec des composés apparentés a pour résultat d'augmenter la capacité qu'ont ces cultures de synthétiser l'acétylcholine servant de neurotransmetteur. L'invention offre des compositions pharmaceutiques comprenant de l'éthanolamine ou des composés apparentés et leurs dérivés, destinés à être utilisés dans le traitement de la maladie d'Alzheimer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5189787A | 1987-05-19 | 1987-05-19 | |
US051,897 | 1987-05-19 | ||
US18800588A | 1988-05-11 | 1988-05-11 | |
US188,005 | 1994-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988009171A1 true WO1988009171A1 (fr) | 1988-12-01 |
Family
ID=26729929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/001693 WO1988009171A1 (fr) | 1987-05-19 | 1988-05-18 | Phosphoethanolamine permettant le traitement de la maladie d'alzheimer |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1790988A (fr) |
IL (1) | IL86423A0 (fr) |
WO (1) | WO1988009171A1 (fr) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5760021A (en) * | 1992-05-29 | 1998-06-02 | The Procter & Gamble Company | Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
EP0774252A4 (fr) * | 1994-05-06 | 2000-04-26 | Kanebo Ltd | Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite |
WO2001010428A3 (fr) * | 1999-08-10 | 2002-06-13 | Yeda Res & Dev | Utilisation de bases n-methyl d'ethanolamine pour prevenir la mort cellulaire induite par le stress oxydant |
US6407061B1 (en) | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
EP1004301A4 (fr) * | 1997-07-28 | 2002-11-13 | Riken | Agent promoteur de protection et de survie des cellules du systeme nerveux central |
EP1060750A3 (fr) * | 1993-03-29 | 2003-03-26 | Queen's University at Kingston | Procédé de traitement de l'amyloidose |
US6693076B1 (en) | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6723699B1 (en) | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
JP2005526046A (ja) * | 2002-02-27 | 2005-09-02 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 上皮及び網膜組織疾患の治療のための組成物及び治療方法 |
US7041314B2 (en) | 2001-05-24 | 2006-05-09 | Neuren Pharmaceuticals Ltd. | GPE analogs and peptidominetics |
US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US7273618B2 (en) | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US7560447B2 (en) | 2000-05-08 | 2009-07-14 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7754761B2 (en) | 1993-03-29 | 2010-07-13 | Bellus Health (International) Limited | Sulfonated compounds and compositions for treating amyloidosis |
US8372886B2 (en) | 2005-12-22 | 2013-02-12 | Kiacta Sarl | Treatment of renal disorders, diabetic nephropathy and dyslipidemias |
US8835654B2 (en) | 2004-12-22 | 2014-09-16 | Bhi Limited Partnership | Method and compositions for treating amyloid-related diseases |
US9499480B2 (en) | 2006-10-12 | 2016-11-22 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
CN114099487A (zh) * | 2021-12-22 | 2022-03-01 | 上海市第一人民医院 | 乙醇胺在制备预防、缓解和/或治疗神经炎症相关疾病的产品中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437834A1 (fr) * | 1978-10-04 | 1980-04-30 | Lejeune Jerome | Compositions pharmaceutiques a base de l-serine ou de glycine |
US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
EP0147185A2 (fr) * | 1983-12-22 | 1985-07-03 | Massachusetts Institute Of Technology | Emploi thérapeutique du cytidyl diphosphocholine pour augmenter l'acétylcholine neuronale |
-
1988
- 1988-05-18 IL IL86423A patent/IL86423A0/xx unknown
- 1988-05-18 WO PCT/US1988/001693 patent/WO1988009171A1/fr unknown
- 1988-05-18 AU AU17909/88A patent/AU1790988A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437834A1 (fr) * | 1978-10-04 | 1980-04-30 | Lejeune Jerome | Compositions pharmaceutiques a base de l-serine ou de glycine |
US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
EP0147185A2 (fr) * | 1983-12-22 | 1985-07-03 | Massachusetts Institute Of Technology | Emploi thérapeutique du cytidyl diphosphocholine pour augmenter l'acétylcholine neuronale |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6693076B1 (en) | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5703045A (en) * | 1989-06-05 | 1997-12-30 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6723699B1 (en) | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5776897A (en) * | 1989-06-05 | 1998-07-07 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6342478B1 (en) | 1989-12-05 | 2002-01-29 | Chiron Corporation | Method for administering fibroblast growth factor to the brain |
US6180603B1 (en) | 1989-12-05 | 2001-01-30 | Chiron Corporation | Method for administering neurologic agents to the brain |
US6313093B1 (en) | 1989-12-05 | 2001-11-06 | Chiron Corporation | Method for administering insulin to the brain |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
US6407061B1 (en) | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
US5760021A (en) * | 1992-05-29 | 1998-06-02 | The Procter & Gamble Company | Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
EP1060750A3 (fr) * | 1993-03-29 | 2003-03-26 | Queen's University at Kingston | Procédé de traitement de l'amyloidose |
US7754761B2 (en) | 1993-03-29 | 2010-07-13 | Bellus Health (International) Limited | Sulfonated compounds and compositions for treating amyloidosis |
EP0774252A4 (fr) * | 1994-05-06 | 2000-04-26 | Kanebo Ltd | Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite |
EP1004301A4 (fr) * | 1997-07-28 | 2002-11-13 | Riken | Agent promoteur de protection et de survie des cellules du systeme nerveux central |
US7273618B2 (en) | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
WO2001010428A3 (fr) * | 1999-08-10 | 2002-06-13 | Yeda Res & Dev | Utilisation de bases n-methyl d'ethanolamine pour prevenir la mort cellulaire induite par le stress oxydant |
US8865687B2 (en) | 2000-05-08 | 2014-10-21 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US8377912B2 (en) | 2000-05-08 | 2013-02-19 | N. V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US7772217B2 (en) | 2000-05-08 | 2010-08-10 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US7560447B2 (en) | 2000-05-08 | 2009-07-14 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7041314B2 (en) | 2001-05-24 | 2006-05-09 | Neuren Pharmaceuticals Ltd. | GPE analogs and peptidominetics |
JP2005526046A (ja) * | 2002-02-27 | 2005-09-02 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 上皮及び網膜組織疾患の治療のための組成物及び治療方法 |
JP4745610B2 (ja) * | 2002-02-27 | 2011-08-10 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 上皮及び網膜組織疾患の治療のための組成物及び治療方法 |
US7598269B2 (en) | 2003-06-23 | 2009-10-06 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US8835654B2 (en) | 2004-12-22 | 2014-09-16 | Bhi Limited Partnership | Method and compositions for treating amyloid-related diseases |
US8372886B2 (en) | 2005-12-22 | 2013-02-12 | Kiacta Sarl | Treatment of renal disorders, diabetic nephropathy and dyslipidemias |
US9499480B2 (en) | 2006-10-12 | 2016-11-22 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US10238611B2 (en) | 2006-10-12 | 2019-03-26 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US10857109B2 (en) | 2006-10-12 | 2020-12-08 | Bellus Health, Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US11020360B2 (en) | 2006-10-12 | 2021-06-01 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
CN114099487A (zh) * | 2021-12-22 | 2022-03-01 | 上海市第一人民医院 | 乙醇胺在制备预防、缓解和/或治疗神经炎症相关疾病的产品中的应用 |
CN114099487B (zh) * | 2021-12-22 | 2025-04-22 | 上海市第一人民医院 | 乙醇胺在制备预防、缓解和/或治疗神经炎症相关疾病的产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
IL86423A0 (en) | 1988-11-15 |
AU1790988A (en) | 1988-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1988009171A1 (fr) | Phosphoethanolamine permettant le traitement de la maladie d'alzheimer | |
US4923696A (en) | Method to prepare a neurotrophic composition | |
Williams et al. | Exogenous nerve growth factor increases the activity of high‐affinity choline uptake and choline acetyltransferase in brain of Fisher 344 male rats | |
US4699875A (en) | Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors | |
EP0348353B1 (fr) | Application de substances physiologiquement actives pour la fabrication de médicaments pour les maladies cérébrales et nerveuses | |
US6165515A (en) | Method for treatment of osteoporosis | |
US6262024B1 (en) | Neuron regulatory factor for promoting neuron survival | |
EP2389171B1 (fr) | Utilisation de composés ptérosine pour traiter le diabète et l'obésité | |
Jones et al. | Oral zinc supplements in non-responsive coeliac syndrome: effect on jejunal morphology, enterocyte production, and brush border disaccharidase activities. | |
US5017375A (en) | Method to prepare a neurotrophic composition | |
EP2441459A1 (fr) | Propriétés neuroprotectrice de la 5'-méthylthioadénosine | |
EP1004301A1 (fr) | Agent promoteur de protection et de survie des cellules du systeme nerveux central | |
DE69218222T2 (de) | Neue ganglioside-derivaten | |
DE69231930T2 (de) | Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie | |
EP0082612B1 (fr) | Préparations pour le traitement de la sclérose amyotrophique latérale, la maladie de Parkinson et la maladie d'Alzheimer par des facteurs neurotrophiques | |
Sbaschnig‐Agler et al. | Ganglioside changes in the regenerating goldfish optic system: Comparison with glycoproteins and phospholipids | |
US4119618A (en) | Vasoactive polypeptide and method of preparation from neural tissue | |
DE69838303T2 (de) | Derivate hydroxyprolin | |
NZ221527A (en) | Scymnol sulphates | |
Shah et al. | Effect of postweaning hyperphenylalaninemia on brain development in rats: myelination, lipid, and fatty acid composition of myelin | |
Kalasz et al. | Identification of N-methylated basic amino acids from human adult teeth | |
US7385024B2 (en) | Heterocarpine, a human GHRH-binding protein | |
CA2492654A1 (fr) | Proteine immunosuppressive humaine | |
Dux et al. | Serum prevents glutamate-induced mitochondrial calcium accumulation in primary neuronal cultures | |
NZ537846A (en) | Heterocarpine, a plant-derived protein with anti-cancer properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |